This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

maraviroc (Celsentri®)

Reference No. 3511

Publication date:

Appraisal information

maraviroc (Celsentri®) 25 mg film-coated tablet
maraviroc (Celsentri®) 75 mg film-coated tablet
maraviroc (Celsentri®) 150 mg film-coated tablet
maraviroc (Celsentri®) 300 mg film-coated tablet
maraviroc (Celsentri®) 20 mg/ml oral solution

Company: ViiV Healthcare UK Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/10/2017

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, maraviroc (Celsentri®) cannot be endorsed for use within NHS Wales in combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable.
Statement of Advice (SOA)